454 Life Sciences, a member of the Roche group, and a Yale School of Medicine researcher have announced that they have used the company's Genome Sequencer? system to identify previously undetectable rare drug resistant HIV variants in samples from an earlier performed clinical trial. The work, presented by Michael Kozal, M.D. [click link for full article]
More...